Magda Marquet Sells 11,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Magda Marquet sold 11,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $48.23, for a total transaction of $530,530.00. Following the transaction, the director owned 9,930 shares in the company, valued at $478,923.90. This represents a 52.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

AnaptysBio Trading Down 1.4%

Shares of NASDAQ:ANAB opened at $45.68 on Friday. The stock has a market capitalization of $1.26 billion, a PE ratio of -16.20 and a beta of 0.32. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $52.47. The firm has a fifty day moving average price of $43.71 and a 200 day moving average price of $32.39.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has authorized a stock buyback program on Friday, November 21st that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research report on Monday, November 24th. Truist Financial lifted their target price on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.40.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Larson Financial Group LLC grew its position in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 1,292 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares during the period. Finally, Profund Advisors LLC bought a new stake in shares of AnaptysBio during the third quarter valued at approximately $201,000.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.